Systematic Investigation of Time Windows for Adverse Event Data Mining for Recently Approved Drugs

Journal of Clinical Pharmacology

Volumn 49, Issue 6, 2009, Pages 626-633

  Hochberg, Alan M ^a   Hauben, Manfred ^b,c,d,e   Pearson, Ronald K ^a   O'Hara, Donald J ^a   Reisinger, Stephanie J ^a  

^a ProSanos Corporation   (United States)

^b PFIZER INC   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

Data mining; Pharmacovigilance; Time to signal

Indexed keywords

ADEFOVIR DIPIVOXIL; AMLODIPINE; APOMORPHINE; ARIPIPRAZOLE; AZACITIDINE; BEHENYL ALCOHOL; CEVIMELINE; CLOFARABINE; DARIFENACIN; ELETRIPTAN; ERLOTINIB; EZETIMIBE; GADOBENATE DIMEGLUMINE; HIRULOG; ICODEXTRIN; LANTHANUM CARBONATE; MIFEPRISTONE; NITAZOXANIDE; OLMESARTAN; PEGAPTANIB; PREGABALIN; RIVASTIGMINE; ROSIGLITAZONE; SOLIFENACIN; TELITHROMYCIN; TINZAPARIN; TROSPIUM CHLORIDE; UNINDEXED DRUG; UNIPROST; UNOPROSTONE ISOPROPYL ESTER;

ARTICLE; DATA MINING; DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; POSTMARKETING SURVEILLANCE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; DRUG TOXICITY; HUMANS; INFORMATION STORAGE AND RETRIEVAL; PHARMACEUTICAL PREPARATIONS; TIME FACTORS;

EID: 67049119563     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009333484     Document Type: Article

References (12)

1. Syed RA, Marks NS, Goetsch RA. Spontaneous reporting in the United States. In: Strom BL, Kimmel SE, eds. Textbook of Pharmacoepidemiology. West Sussex, England: John Wiley; 2006:91-116.
2. Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf. 2003;12:559-574.
3. Meyboom RHB, Lindquist M, Egberts ACG, Edwards IR. Signal selection and follow-up in pharmacovigilance. Drug Saf. 2002;25:459-465.
4. Hauben M, Reich L. Communication of findings in pharmacovigilance: use of the term "signal" and the need for precision in its use. Eur J Clin Pharmacol. 2005;61:479-480.
5. Ivkovic S, Saunders G, Ghosh R, et al. Using association and overlapping time window approach to detect drug reaction signals. In: Proceedings of the 2005 International Conference on Computational Intelligence for Modeling, Control and Automation, and International Conference on Intelligent Agents, Web Technologies and Internet Commerce (CIMCA-IAWTIC '05): Volume 1. Washington, DC: IEEE Computer Society; 2005:1045-1053.
6. Kulldorff M, Mostashari F, Duczmal L, et al. Multivariate scan statistics for disease surveillance. Stat Med. 2007;26:1824-1833.
7. Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007;45(suppl 2):S89-S95.
8. Brown SM, Benneyan JC, Theobald DA, et al. Binary cumulative sums and moving averages in nosocomial infection cluster detection. Persist Infect Dis. 2002;8:1426-1432.
9. Hochberg AM, Hauben M, Pearson RK, et al. An evaluation of three signal detection algorithms using a highly inclusive reference event database. Drug Saf. In press.
10. Hochberg AM, Reisinger SJ, Pearson RK, et al. Using data mining to predict safety actions from FDA adverse event reporting system data. Drug Inf J. 2007;41:633-644.
11. Ross SM. Introduction to Probability Models. New York: Academic Press; 1972.
12. Weber JCP. Epidemiology of adverse reactions to nonsteroi-dal antiinflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances in Inflammation Research: Volume 6. New York: Raven; 1984:1-6.